Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: Lessons from tramadol

Biological Psychology

Volumn 73, Issue 1, 2006, Pages 90-99

  Epstein, David H ^a   Preston, Kenzie L ^a   Jasinski, Donald R ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abuse liability assessment; Cross species comparison; Drug abuse dependence; Oxycodone

Indexed keywords

BUPRENORPHINE; LEFETAMINE; LEVALLORPHAN; METHADONE; MORPHINE; NALBUPHINE; NALOXONE; NALTREXONE; OPIATE; OPIATE ANTAGONIST; OXYCODONE; PENTAZOCINE; PLACEBO; TRAMADOL;

ABDOMINAL CRAMP; ANALGESIA; ANIMAL BEHAVIOR; ANTINOCICEPTION; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; BONE PAIN; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFUSION; DATA ANALYSIS; DEPERSONALIZATION; DEPRESSION; DIARRHEA; DRUG ABUSE; DRUG DEPENDENCE; DRUG MARKETING; DRUG SELF ADMINISTRATION; DRUG TOLERANCE; ENANTIOMER; FOOD AND DRUG ADMINISTRATION; GOOSEFLESH; HALLUCINATION; HUMAN; INFORMATION PROCESSING; INSOMNIA; LACRIMATION DISORDER; MOUSE STRAIN; NAUSEA; NONHUMAN; OPIATE ADDICTION; PAIN; PANIC; PARANOIA; PARESTHESIA; PLACE PREFERENCE; POSTMARKETING SURVEILLANCE; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; RACEMIC MIXTURE; RAT STRAIN; RESTLESSNESS; RHESUS MONKEY; RHINORRHEA; SENSORY DYSFUNCTION; SKIN TINGLING; SWEATING; TINNITUS; TREATMENT DURATION; UNITED STATES; VOMITING; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PRODUCT SURVEILLANCE, POSTMARKETING; RECEPTORS, OPIOID; SELF ADMINISTRATION; SPECIES SPECIFICITY; TRAMADOL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33646530497     PISSN: 03010511     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsycho.2006.01.010     Document Type: Article

References (77)

1. Aceto M.D., McKean D.B., and Pearl J. Effects of opiates and opiate antagonists on the Straub tail reaction in mice. British Journal of Pharmacology 36 2 (1969) 225-239
2. Bamigbade T.A., Davidson C., Langford R.M., and Stamford J.A. Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. British Journal of Anaesthesia 79 3 (1997) 352-356
3. Bardo M.T., and Bevins R.A. Conditioned place preference: what does it add to our preclinical understanding of drug reward?. Psychopharmacology 153 1 (2000) 31-43
4. Barsotti C.E., Mycyk M.B., and Reyes J. Withdrawal syndrome from tramadol hydrochloride. American Journal of Emergency Medicine 21 1 (2003) 87-88
5. Bogetto F., Bellino S., Revello R.B., and Patria L. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. CNS Drugs 16 4 (2002) 273-283
6. Brady J.V., and Lukas S.E. Testing drugs for physical dependence potential and abuse liability. NIDA Research Monograph (1984) 52
7. Branch M.N. Behavioral factors in drug tolerance. In: van Haaren F. (Ed). Methods in Behavioral Pharmacology (1993), Elsevier, Amsterdam
8. Breen C.L., Harris S.J., Lintzeris N., Mattick R.P., Hawken L., Bell J., et al. Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug and Alcohol Dependence 71 1 (2003) 49-55
9. Broadbear J.H., Sumpter T.L., Burke T.F., Husbands S.M., Lewis J.W., Woods J.H., et al. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine. Journal of Pharmacology and Experimental Therapeutics 294 3 (2000) 933-940
10. Cami J., Lamas X., and Farre M. Acute effects if tramadol in methadone-maintained volunteers. Drugs 47 (1994) 39-43
11. Cicero T., Adams E., Geller A., Inciardi J., Munoz A., Schnoll S., et al. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug and Alcohol Dependence 57 (1999) 7-22
12. Clark M.J., Emmerson P.J., Mansour A., Akil H., Woods J.H., Portoghese P.S., et al. Opioid efficacy in a C6 glioma cell line stably expressing the delta opioid receptor. Journal of Pharmacology and Experimental Therapeutics 283 2 (1997) 501-510
13. Collins R., Weeks J., Cooper M., Good P., and Russell R. Prediction of abuse liability of drugs using IV self-administration by rats. Psychopharmacology 82 (1984) 6-13
14. Corrigan O.P. A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises. Social Science and Medicine 55 3 (2002) 497-507
15. DEA, 2003. 21 USC, Section 811. Retrieved January 8, 2004. From http://www.deadiversion.usdoj.gov/21cfr/21usc/811.htm.
16. Dewey W.L., Snyder J.W., Harris L.S., and Howes J.F. The effect of narcotics and narcotic antagonists on the tail-flick response in spinal mice. Journal of Pharmacy and Pharmacology 21 8 (1969) 548-550
17. Driessen B., and Reimann W. Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro. British Journal of Pharmacology 105 1 (1992) 147-151
18. Driessen B., Reimann W., and Giertz H. Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro. British Journal of Pharmacology 108 3 (1993) 806-811
19. Ehrenreich H., and Poser W. Dependence on tramadol. Clinical Investigator 72 1 (1993) 76
20. Eissenberg T., Johnson R.E., Bigelow G.E., Walsh S.L., Liebson I.A., Strain E.C., et al. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug and Alcohol Dependence 45 (1997) 81-91
21. Fraser H., VanHorn G., Martin W., Wolbach A., and Isbell H. Methods for evaluating addiction liability. (A) "attitude" of opiate addicts toward opiate-like drugs, (B) a short-term "direct" addiction test. Journal of Pharmacology and Experimental Therapeutics 133 3 (1961) 371-387
22. Freye E., and Levy J. Acute abstinence syndrome following abrupt cessation of long-term use of tramadol (Ultram): a case study. European Journal of Pain 4 3 (2000) 307-311
23. Friderichs E., Felgenhauer F., Jongschaap P., and Osterloh G. Pharmacological studies on analgesia, dependence on and tolerance of tramadol, a potent analgetic drug (author's transl). Arzneimittelforschung 28 1a (1978) 122-134
24. Gillen C., Haurand M., Kobelt D.J., and Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn-Schmiedebergs Archives of Pharmacology 362 2 (2000) 116-121
25. Glass P.S., Jhaveri R.M., and Smith L.R. Comparison of potency and duration of action of nalmefene and naloxone. Anesthesia and Analgesia 78 (1994) 536-541
26. Greenwald M.K., Schuh K.J., and Stine S.M. Transferring methadone-maintained outpatients to the buprenorphine sublingual tablet: a preliminary study. American Journal on Addictions 12 4 (2003) 365-374
27. Gutstein H.B., and Akil H. Opioid analgesics. In: Hardman J.G., and Limbird L.E. (Eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics (2001), McGraw-Hill, New York, NY 569-619
28. Haertzen C. Development of scales based on patterns of drug effects, using the addiction research center inventory (ARCI). Psychological Reports 18 (1966) 163-194
29. Hayes A.G., Birch P.J., Rogers H., and Sheehan M.J. Use of isolated tissue preparations to evaluate opioid drugs of abuse. In: Adler M.W., and Cowan A. (Eds). Testing and Evaluation of Drugs of Abuse Vol. 6 (1990), Wiley-Liss, New York 19-32
30. Howes J.F. A simple, reliable method for predicting the physical dependence liability of narcotic antagonist analgesics in the rat. Pharmacology Biochemistry and Behavior 14 5 (1981) 689-692
31. Jasinski D.R. Assessment of the abuse potentiality of morphinelike drugs (methods used in man). In: Martin W.R. (Ed). Drug Addiction 1: Morphine, sedative/hypnotic and alcohol dependence (1977), Springer-Verlag, Berlin
32. Jasinski D.R., and Mansky P.A. Evaluation of nalbuphine for abuse potential. Clinical Pharmacology and Therapeutics 13 1 (1972) 78-90
33. Jasinski D.R., Pevnick J.S., and Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Archives of General Psychiatry 35 4 (1978) 501-516
34. Jasinski D.R., Preston K., Sullivan J.T., and Testa M.P. Abuse potential of oral tramadol. NIDA Research Monograph 132 (1993) 103
35. Jasinski D.R., Sullivan J.T., and Testa M. Abuse potential of IV tramadol. Paper presented at the 55th Annual Scientific Meeting of the College on Problems of Drug Dependence (1994)
36. Jones H.E., Johnson R.E., Fudala P.J., Henningfield J.E., and Heishman S.J. Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans. Drug and Alcohol Dependence 60 1 (2000) 29-37
37. Kishioka S., Paronis C.A., Lewis J.W., and Woods J.H. Buprenorphine and methoclocinnamox: agonist and antagonist effects on respiratory function in rhesus monkeys. European Journal of Pharmacology 391 3 (2000) 289-297
38. Knisely J.S., Campbell E.D., Dawson K.S., and Schnoll S.H. Tramadol post-marketing surveillance in health care professionals. Drug and Alcohol Dependence 68 1 (2002) 15-22
39. Lange-Asschenfeldt C., Weigmann H., Hiemke C., and Mann K. Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology. Journal of Clinical Psychopharmacology 22 4 (2002) 440-441
40. Lehmann K.A., Kratzenberg U., Schroeder-Bark B., and Horrichs-Haermeyer G. Postoperative patient-controlled analgesia with tramadol: analgesic efficacy and minimum effective concentrations. Clinical Journal of Pain 6 3 (1990) 212-220
41. Leo R.J., Narendran R., and DeGuiseppe B. Methadone detoxification of tramadol dependence. Journal of Substance Abuse Treatment 19 3 (2000) 297-299
42. Lintz W., Erlacin S., Frankus E., and Uragg H. Biotransformation of tramadol in man and animal (author's transl). Arzneimittelforschung 31 11 (1981) 1932-1943
43. Martin W., and Jasinski D.R. Assessment of the abuse potential of narcotic analgesics in animals. In: Born G., Eichler O., Farah A., Herken H., and Welch A. (Eds). Handbook of Experimental Pharmacology. 45th ed. (1977), Springer-Verlag, Berlin 159-196
44. Mello N.K., and Mendelson J.H. Buprenorphine suppresses heroin use by heroin addicts. Science 207 8 (1980) 657-659
45. Miranda H.F., and Pinardi G. Antinociception, tolerance, and physical dependence comparison between morphine and tramadol. Pharmacology Biochemistry and Behavior 61 4 (1998) 357-360
46. Murano T., Yamamoto H., Endo N., Kudo Y., Okada N., Masuda Y., et al. Studies on dependence on tramadol in rats. Arzneimittelforschung 28 1a (1978) 152-158
47. Nickel B., and Aledter A. Comparative physical dependence studies in rats with flupirtine and opiate receptor stimulating analgesics. Postgraduate Medical Journal 63 Suppl. 3 (1987) 41-43
48. Overton D.A. Applications and limitations of the drug discrimination method for the study of drug abuse. In: Bozarth M.A. (Ed). Methods of assessing the reinforcing properties of abused drugs (1987), Springer-Verlag, New York 291-340
49. Preston K.L., and Bigelow G.E. Subjective and discriminative effects of drugs. Behavioural Pharmacology 2 4-5 (1991) 293-313
50. Preston K.L., Bigelow G.E., and Liebson I.A. Self-administration of clonidine, oxazepam, and hydromorphone by patients undergoing methadone detoxification. Clinical Pharmacology and Therapeutics 38 2 (1985) 219-227
51. Preston K.L., Jasinski D.R., and Testa M. Abuse potential and pharmacological comparison of tramadol and morphine. Drug and Alcohol Dependence 27 1 (1991) 7-17
52. Raffa R.B., Friderichs E., Reimann W., Shank R.P., Codd E.E., and Vaught J.L. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an "atypical" opioid analgesic. Journal of Pharmacology and Experimental Therapeutics 260 1 (1992) 275-285
53. Raffa R.B., Friderichs E., Reimann W., Shank R.P., Codd E.E., Vaught J.L., et al. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. Journal of Pharmacology and Experimental Therapeutics 267 1 (1993) 331-340
54. Reeves R.R., and Liberto V. Abuse of combinations of carisoprodol and tramadol. Southern Medical Journal 94 5 (2001) 512-514
55. Ren Y.H., and Zheng J.W. Influence of tramadol on morphine discriminative behavior in rats. Acta Pharmacologica Sinica 21 10 (2000) 924-926
56. Richter W., Barth H., Flohe L., and Giertz H. Clinical investigation on the development of dependence during oral therapy with tramadol. Arzneimittelforschung 35 11 (1985) 1742-1744
57. Rosenbaum J.F., Fava M., Hoog S.L., Ascroft R.C., and Krebs W.B. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biological Psychiatry 44 2 (1998) 77-87
58. SAMHSA, 2003a. The DASIS report: treatment admissions involving narcotic painkillers. Retrieved January 9, 2004. From http://www.samhsa.gov/oas/2k3/painTX/painTX.htm.
59. SAMHSA, 2003b. Nonmedical use of prescription-type drugs among youths and young adults. Retrieved January 9, 2004. From http://www.samhsa.gov/oas/2k3/prescription/prescription.htm.
60. SAMHSA, 2003c. Overview of findings from the 2002 national survey on drug use and health. Retrieved January 9, 2004. From http://www.samhsa.gov/oas/NHSDA/2k2NSDUH/Results/2k2results.htm.
61. Schuh K.J., Walsh S.L., Bigelow G.E., Preston K.L., and Stitzer M.L. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans. Journal of Pharmacology and Experimental Therapeutics 278 2 (1996) 836-846
62. Senay E.C., Adams E.H., Geller A., Inciardi J.A., Munoz A., Schnoll S.H., et al. Physical dependence on Ultram (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur. Drug and Alcohol Dependence 69 3 (2003) 233-241
63. Sprague J.E., Leifheit M., Selken J., Milks M.M., Kinder D.H., and Nichols D.E. In vivo microdialysis and conditioned place preference studies in rats are consistent with abuse potential of tramadol. Synapse 43 2 (2002) 118-121
64. Swedberg M.D., Shannon H.E., Nickel B., and Goldberg S.R. Pharmacological mechanisms of action of flupirtine: a novel, centrally acting, nonopioid analgesic evaluated by its discriminative effects in the rat. Journal of Pharmacology and Experimental Therapeutics 246 3 (1988) 1067-1074
65. Swedberg M.D., Shannon H.E., Nickel B., and Goldberg S.R. D-16949 (anpirtoline): a novel serotonergic (5-HT1B) psychotherapeutic agent assessed by its discriminative effects in the rat. Journal of Pharmacology and Experimental Therapeutics 263 3 (1992) 1015-1022
66. Thomas A.N., and Suresh M. Opiate withdrawal after tramadol and patient-controlled analgesia. Anaesthesia 55 8 (2000) 826-827
67. Tzschentke T.M. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Progress in Neurobiology 56 6 (1998) 613-672
68. Tzschentke T.M., Bruckmann W., and Friderichs E. Lack of sensitization during place conditioning in rats is consistent with the low abuse potential of tramadol. Neuroscience Letters 329 1 (2002) 25-28
69. Valle M., Garrido M.J., Pavon J.M., Calvo R., and Troconiz I.F. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O-desmethyltramadol, in rats. Journal of Pharmacology and Experimental Therapeutics 293 2 (2000) 646-653
70. Walsh S.L., Sullivan J.T., Preston K.L., Garner J.E., and Bigelow G.E. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. Journal of Pharmacology and Experimental Therapeutics 279 (1996) 524-538
71. Willner P. Animal models of addiction. Human Psychopharmacology 12 (1997) 59-68
72. Woody G.E., Senay E.C., Geller A., Adams E.H., Inciardi J.A., Schnoll S., et al. An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride). Drug and Alcohol Dependence 72 2 (2003) 163-168
73. Woolverton W., and Nader M. Experimental evaluation of the reinforcing effects of drugs. Modern Methods in Pharmacology 6 (1990) 165-192
74. Yanagita T. Drug dependence potential of 1-(m-methoxyphenyl)-2-dimethylaminomethyl)-cyclohexan-1-ol hydrochloride (tramadol) tested in monkeys. Arzneimittelforschung 28 1a (1978) 158-163
75. Yates W.R., Nguyen M.H., and Warnock J.K. Tramadol dependence with no history of substance abuse. American Journal of Psychiatry 158 6 (2001) 964
76. Young A. Discriminative stimulus profiles of psychoactive drugs. In: Mello N.K. (Ed). Advances in Substance Abuse. 4th ed. (1991), Jessica Kingsley Publishers, London 140-203
77. Zacny J., Bigelow G., Compton P., Foley K., Iguchi M., and Sannerud C. College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug and Alcohol Dependence 69 3 (2003) 215-232